Neutron and gamma dose distribution for tandem, tandem and ovoid and plaque for intracavitary 252Cf therapy of cervix carcinoma.
252Cf was used to treat tumors of the cervix in an ongoing clinical trial. Tandem and ovoids were used as well as a combination of single and multiple applications. Dosimetric analysis of these treated cases revealed the patterns of neutron dose rate and neutron/gamma ray dose ratios which were achievable using a variety of loading arrangements. Although pelvic tumor reference points and tissue dose was in general similar whether a tandem or tandem plus ovoids were used, vaginal dose was increased over two-fold or more by the use of vaginal applicators and sources. This indicates that a variety of individualized arrangements for different clinical presentations can be used for brachytherapy of gynecological pelvic neoplasm.
D001918:Brachytherapy / Q000379:methods*; D002142:Californium / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005260:Female; D005720:Gamma Rays; D006801:Humans; D009367:Neoplasm Staging; D009502:Neutrons; D011879:Radiotherapy Dosage; D002583:Uterine Cervical Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D014621:Vagina
D002142:Californium